Company
GRAIL
GRAIL develops blood-based cancer screening tests using next-generation sequencing and machine learning to detect multiple cancer types early. The company's Galleri test is designed to identify cancer signals before symptoms appear through analysis of cell-free DNA. GRAIL serves healthcare systems and patients globally, backed by extensive clinical studies involving hundreds of thousands of participants.
GRAIL is a publicly traded company operating in the biotech & pharma sector, based in USA. Leadership tracked by CEOInsider includes Jeff Huber (CEO).
Leadership
Current
Recent developments
AI summary of recent coverageRecent coverage of GRAIL has focused on the company's blood-based cancer detection test, with reporting examining both its commercial availability at price points around $700-$950 and the significant limitations and caveats associated with its claims to detect multiple cancer types. Earlier headlines documented leadership transitions at the company, including the departure of founder Jeff Huber as CEO in 2017 and subsequent executive changes as GRAIL sought to build its commercial capabilities and secure additional backing.
Summarized from the headlines in the sidebar; see each source for the full story.